Hematology

Ibrutinib, both in the frontline setting and in the form of continuous treatment, was associated with improved quality of life over chemoimmunotherapy for patients with chronic lymphocytic leukemia.

If patients with cancer experience depression or anxiety, it can result in low clinical trial enrollment.

Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.

In comparison to physicians’ choice of treatment, ciltacabtagene autoleucel demonstrated significant advantages in progression-free and overall survival, time to next treatment, and overall response rate.

Combining ibrutinib with rituximab resulted in improved 2-year progression-free survival among elderly patients with previously untreated diffuse large B-cell lymphoma.

The FDA has approved the combination of rituximab plus chemotherapy to treat children aged between 6 months and 18 years who have advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

Patients with relapsed/refractory chronic lymphocytic leukemia experienced positive gene set enrichment after receiving ibrutinib in addition to lisocabtagene maraleucel.

Physicians urge patients with lymphoid malignancies to continue precautionary COVID-19 measures regardless of vaccination status.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses the importance of NCCN guidelines in prescribing medications for patients with chronic leukemia. .

Ropeginterferon alfa-2b-njft is now an FDA-approved drug for the treatment of polycythemia vera.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses omacetaxine as a novel regimen in CML treatment.

Findings from biomarker tests for patients with chronic lymphocytic leukemia can help appropriately tailor therapy plans as well as identify patients eligible for clinical trials.

Newer modalities seek to use MRD to provide more definitive prognoses.

The new Cilta-Cel PDUFA decision date is February 28, 2022.

CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.

Ruxolitinib was not associated with an increased risk of secondary malignancies in patients with polycythemia vera.

Parsaclisib has been granted a priority review for 3 indications that include relapsed or refractory follicular, marginal zone, and mantle cell lymphoma.

The FDA have granted an accelerated approval to acimibinib, which treats CML by binding to the ABL myristoyl pocket.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.

Autologous hematopoietic stem-cell transplantation, the standard frontline treatment in treating patients with mantel cell lymphoma, demonstrated superior long-term efficacy compared with interferon alfa in a recent trial.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on the dedication she has observed from caregivers taking care of loved ones with leukemia during the COVID-19 era.

Brexucabtagene autoleucel is now an FDA approved treatment options for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News Co-Editor in Chief, shares her opinion on recent developments in leukemia treatment options.

An expert presenting at the Society of Hematology Oncology 2021 Annual Conference shared important updates in polycythemia vera (PV) treatment and weighed in on the direction of future treatment.

Patients with progressed multiple myeloma experienced deep and durble responses through CAR T-cell therapy ciltacabtagene autoleucel therapy.

Patients with chronic lymphocytic leukemia (CLL) are at an increased risk for infection.

Zanubrutinib received an accelerated approval for the indication of adults with marginal zone lymphoma with at least 1 prior treatment with an anti-CD20-based therapy.

Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.

Due to the favorable efficacy and safety profiles of daratumumab plus lenalidomide and dexamethasone, researchers speculate that the combination may become the new standard of care in multiple myeloma treatment.

Patients with myeloma and a negative MRD may be at a reduced risk of mortality and other progression-free survival events.